Skip to content
10-Q

Quarterly Report

VITASPRING BIOMEDICAL CO. LTD.

0001640334-26-000174

← back to feed
Filed
Jan 30, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Jan 19, 2026 207.03M sh
Current Liabilities Q3 2024 · Oct 31, 2023 $3.44M
Current Liabilities Q3 2024 · Jan 31, 2023 $3.07M
Total Liabilities Q3 2024 · Oct 31, 2023 $3.44M
Total Liabilities Q3 2024 · Jan 31, 2023 $3.16M
Current Assets Q3 2024 · Oct 31, 2023 $106.31K
Current Assets Q3 2024 · Jan 31, 2023 $437.08K
Total Assets Q3 2024 · Oct 31, 2023 $277.35K
Total Assets Q3 2024 · Jan 31, 2023 $765.95K
Gross Profit Q3 2024 · Oct 31, 2023 $0
Gross Profit Q3 2024 · Oct 31, 2023 $0
Gross Profit Q3 2024 · Oct 31, 2022 $0
Gross Profit Q3 2024 · Oct 31, 2022 $568K
Cost Of Revenue Q3 2024 · Oct 31, 2023 $0
Cost Of Revenue Q3 2024 · Oct 31, 2023 $0
Cost Of Revenue Q3 2024 · Oct 31, 2022 $0
Cost Of Revenue Q3 2024 · Oct 31, 2022 $922K
Shares Diluted Q3 2024 · Oct 31, 2022 206.52M sh
Shares Diluted Q3 2024 · Oct 31, 2022 206.52M sh
Operating Cash Flow restated Q3 2024 · Oct 31, 2022 −$83.16K
Stockholders Equity Q3 2024 · Oct 31, 2022 $1.68M
Stockholders Equity Q3 2024 · Jul 31, 2022 $1.78M
Stockholders Equity Q3 2024 · Apr 30, 2022 $1.89M
Stockholders Equity Q3 2024 · Jan 31, 2022 $1.58M
Eps Diluted Q3 2024 · Oct 31, 2022 $0.00
Eps Diluted Q3 2024 · Oct 31, 2022 $0.00
Sga Expense restated Q3 2024 · Oct 31, 2022 $183.22K
Sga Expense Q3 2024 · Oct 31, 2022 $582.6K
Net Income Q3 2024 · Oct 31, 2022 −$138.28K
Net Income Q3 2024 · Oct 31, 2022 −$5.76K
Net Income Q3 2024 · Jul 31, 2022 −$144.14K
Net Income Q3 2024 · Apr 30, 2022 $276.66K
Operating Income restated Q3 2024 · Oct 31, 2022 −$183.22K
Operating Income restated Q3 2024 · Oct 31, 2022 −$14.6K
Revenue Q3 2024 · Oct 31, 2022 $0
Revenue Q3 2024 · Oct 31, 2022 $1.49M